Acarix AB (publ) (ACIXF)
Acarix AB (publ) operates in the Medical - Devices industry of the Healthcare sector, headquartered in Malmö, SN, SE. The stock last traded at $0.02, up 0.00% on the session, giving a market capitalisation of $25.8M. On trailing twelve-month figures it carries a trailing P/E of -5.91, a net margin of -427.0%. Its beta of -0.22 implies it has historically moved less than the broad market.
Acarix AB (publ) operates as a medical technology enterprise, specializing in the development of swift, AI-powered diagnostic tools designed to exclude coronary artery disease (CAD). These solutions are deployed both within Sweden and on an international scale. The company's principal product is the CADScor System, an innovative diagnostic support device intended for immediate patient assessment. This system leverages precise acoustic measurements and sophisticated artificial intelligence algorithms to scrutinize blood flow within a patient's coronary arteries. Established in 2009, the firm maintains its corporate headquarters in Malmö, Sweden.
Acarix AB (publ) is most often compared with the following Healthcare names: